Skip to main content
Figure 4 | BMC Pulmonary Medicine

Figure 4

From: Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Figure 4

Improvement in TDI focal score at 24 weeks (ITT population). Data are presented as least squares means (SE). ***p < 0.001 vs placebo. FDC, aclidinium/formoterol fixed-dose combination; ITT, intent-to-treat; MCID, minimum clinically important difference; SE, standard error; TDI, transition dyspnoea index.

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us